Celldex Therapeutics (NASDAQ:CLDX) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• Celldex Therapeutics' share price surpassed its 200-day moving average of $21.58, reaching a high of $27.44 before last trading at $26.47.
• The company reported a quarterly EPS of ($0.85), beating estimates, but had a negative net margin of 3,446.88% and revenue below analyst expectations.
• Analyst ratings are mixed; 7 analysts have a buy rating, but Weiss Ratings maintains a "sell" rating with a consensus target price of $43.78.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $21.58 and traded as high as $27.44. Celldex Therapeutics shares last traded at $26.47, with a volume of 964,066 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Barclays assumed coverage on shares of Celldex Therapeutics in a report on Monday. They issued an "underweight" rating and a $25.00 target price on the stock. HC Wainwright cut their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating on the stock in a report on Wednesday, August 20th. Wells Fargo & Company cut their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating on the stock in a report on Wednesday, August 20th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $43.78.

Celldex Therapeutics Trading Down 2.4%

The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -8.79 and a beta of 1.33. The firm's 50 day simple moving average is $24.21 and its 200-day simple moving average is $21.58.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.01. The company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. As a group, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its position in shares of Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 881 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 501 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Celldex Therapeutics by 6,665.9% during the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 2,933 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics during the 2nd quarter worth $125,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Celldex Therapeutics by 289.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company's stock worth $147,000 after purchasing an additional 5,387 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.